Evidence map›Paper›PMID 28824233›Full record

ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2017

Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia.

Korosh Ashrafi Dehkordi, Morteza Hashemzadeh Chaleshtori, Mohamadreza Sharifi, Ali Jalili, Fardin Fathi, Daem Roshani, Bahram Nikkhoo, Mohammad Saeed Hakhamaneshi, Mohammad Reza Mahmoodian Sani, Mahboue Ganji-Arjenaki

Open access · greenAbstract read
In one paragraph

Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Pharmacogenetics and Personalized Medicine in Hematology.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Korosh Ashrafi DehkordiStudent Research Committee, Kurdistan University of Medical Sciences, Pasdaran Street, Sanandaj, 66177-13446 Iran.ORCID 0000-0001-7105-731X
Morteza Hashemzadeh ChaleshtoriCellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Mohamadreza SharifiDepartment of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Ali JaliliCellular and Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Fardin FathiCellular and Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Daem RoshaniSocial Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Bahram NikkhooDepartment of Pathology and Clinical Laboratory Sciences, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Mohammad Saeed HakhamaneshiCellular and Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Mohammad Reza Mahmoodian SaniResearch Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Mahboue Ganji-ArjenakiDepartment of Genetics, Faculty of Basic Sciences, Shahrekord University, Shahrekord, Iran.
Kurdistan University of Medical Sciences · IRHamedan University of Medical Sciences · IRIsfahan University of Medical Sciences · IRShahrekord University · IRShahrekord University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) are small regulatory molecules that negatively regulate gene expression by base-pairing with their target mRNAs. miRNAs have contribute significantly to cancer biology and recent studies have demonstrated the oncogenic or tumor-suppressing role in cancer cells. In many tumors up-regulation miRNAs has been reported especially miR-222 has been shown to be up-regulated in B chronic lymphocytic leukemia (B-CLL). In this study we assessed the effected inhibition of miR-222 in cell viability of B-CLL. We performed inhibition of mir-222 in B-CLL cell line (183-E95) using locked nucleic acid (LNA) antagomir. At different time points after LNA-anti-mir-222 transfection, miR-222 quantitation and cell viability were assessed by qRT-real time polymerase chain reaction and MTT assays. The data were analyzed by independent

Indexed as

Chronic lymphocytic leukemiaLocked nucleic acidMicroRNAmiR-222

Identifiers

PMID28824233
PMCPMC5544625
OpenAlexW2421992428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.